Introduction
The factors associated with spontaneous and treatmentinduced hepatitis C virus (HCV) clearance are not well defined, but likely involve a combination of host and viral factors. Studies have reported correlations between rate of resolution and host human leukocyte antigen (HLA) polymorphisms, host demographics (including age at infection, sex, race/ethnicity), co-existing viral infections, and other cofactors. Neither the strength of these effects nor the extent to which they are generalizable to different infected populations is well defined. In most instances, genetic analyses that study the host immune response genes in HCV spontaneous clearance are separate from studies that look at genetic factors associated with treatment-induced response to HCV. The factors influencing both these conditions could be distinct and controlled by different genes, or could be similar, which is suggested by similar demographic correlates (sex; race/ethnicity) of spontaneous and treatment-induced clearance. However, recent groundbreaking genetic association studies summarized in this review link polymorphisms in the IL-28B gene to virus elimination in both spontaneous and treatment-induced HCV clearance. Therefore, in this review, we will discuss the host genetic correlates pertaining to both instances, spontaneous and treatment-induced HCV clearance. There has been extensive research that has led to compelling evidence that HCV clearance is also influenced by viral factors, including genotype, inoculum, route, quasispecies diversity and evolution, and by timing and strength of adaptive immune response in newly infected individuals. However, viral factors and adaptive Purpose of review Host genetic factors influencing hepatitis C virus (HCV) transmission outcomes are incompletely defined. However, vast differences observed in rates of spontaneous clearance between individuals infected with the same parental HCV strain strongly indicate a role for genetic determinants in the host immune response to HCV. This review discusses genetic association studies, particularly those published in the last year, that show gene linkages with spontaneous and treatment-induced HCV clearance. The valuable role that blood collection centers can play in increasing the sample size of HCV-confirmed seropositive donors with resolved versus persistent infections for largescale genetic association studies is highlighted.
Recent findings
Recent groundbreaking genome-wide association study and targeted single-nucleotide polymorphism (SNP) analysis from independent groups have demonstrated immune response gene polymorphisms, and particularly in the interleukin (IL)-28B gene, that are strongly linked to HCV clearance. The IL-28B gene encodes interferon lambda 3, an innate immune response cytokine. SNPs in the promoter region of IL-28B were first shown to be associated with HCV treatment-induced viral clearance and subsequently to be a key determinant of spontaneous HCV resolution in infected individuals. Samples from blood donors with resolved and chronic HCV infections have contributed to these findings. Summary These genetic studies have provided the strongest evidence so far of a host genetic determinant linked to HCV clearance. Such large-scale genetic association studies will promote better understanding of HCV disease pathogenesis and assist in effective prognosis of HCV in the future. Continued and preferably expanded participation of blood centers in this research is encouraged. immune responses associated with HCV clearance have not proven to be as important as originally hypothesized and are not discussed in this review; interested readers are directed to other recent reviews [1-5].
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Epidemiology and clinical course of hepatitis C virus infection
In the 20 years since its identification, HCV has emerged as a major etiological agent of liver disease throughout the world. Globally, there are an estimated 170 million people infected with HCV, including nearly 4 million cases in the USA [6, 7] . As a result of donor screening and behavioral changes related to the AIDS epidemic, HCV incidence has declined in the USA over the last decade [8, 9] . However, there are still an estimated 17 000 new infections occurring annually [10] . In Europe and North America, HCV genotypes 1, 2, and 3 are prevalent, with a predominance of genotype 1-infected individuals.
Most of what is known about the very early events in HCV infection has been learned from studies of blood and plasma donors identified by RNA screening, archived samples from recipients in transfusion-associated infections and from experimentally infected chimpanzees [2, [11] [12] [13] [14] [15] . Figure 1 is a schematic representation of the clinical and virological course of HCV in spontaneous resolvers versus chronically infected individuals. Of persons acutely infected with HCV, 20-30% recover spontaneously and clear viremia shortly following serocon-version, whereas 70-80% develop persistent infection. Of the chronically infected individuals, 30% will have progressively worsening liver disease potentially culminating in cirrhosis or hepatocellular carcinoma, 40% will have slowly evolving infections with only modest liver damage and 30% will have viremia in the absence of clinically detectable liver damage. However, for a given infected individual, there is currently no way of predicting prognosis.
Although new HCV antiviral drugs, including protease inhibitors, are in development and clinical trials appear promising, the current standard of care treatment consists of pegylated interferon-a in combination with ribavirin that must be given for 24-48 weeks depending on genotype and virological response [16] [17] [18] . Added to the lengthy treatment course is the complication of extensive side-effects associated with these drugs. Using this regime, 54-63% of individuals with persistent infection exhibited a sustained virological response (SVR), which is believed to represent true eradication of HCV infection [19, 20] . However, the SVR rates for genotype 1-infected individuals are lower at 42-52% as compared with that for individuals infected with genotype 2 or 3 at 76-84%. Hepatitis C virus (HCV) RNA typically becomes detectable within 7-14 days after exposure and specific antibodies appear within 20-150 days, with a mean of approximately 60 days. Elevation of alanine aminotransferases (ALTs) correlates with early immune responses and occurs after week 6, but may occur as early as the second week following exposure. Enzyme immunoassay (EIA) detects antibodies to HCV. The recombinant immunoblot assay (RIBA) identifies the specific antigens to which antibodies are reacting in EIA.
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white patients more likely to clear virus spontaneously than African-American patients. This was also found to be true for treatment-induced viral elimination, with African-Americans less likely to achieve a SVR to therapy than whites [22, 23] . In particular, HCV displays vastly different prognosis to interferon-a therapy in chronically infected individuals from different racial/ ethnic groups who are infected with genotype 1 virus. The differences observed in either spontaneous or treatment-induced HCV elimination suggested that there may be a strong genetic contribution, perhaps manifested phenotypically in more or less robust host immune responses against HCV. The examination of HCV infection and immune response genes has been hampered in part by the lack of in-bred and out-bred animal models for HCV in which host genetics could be studied in the context of acute infection and longitudinal outcome studies of genetically heterogeneous groups of animals. Consequently, investigators have mostly studied HCV-infected human cohorts in an effort to identify specific gene variants ('candidate genes') with demonstrable antiviral effects for immune correlates of HCV recovery.
As with many infectious agents, investigators first looked for associations between HCV resolution and polymorphisms at both class I HLA and class II HLA loci. Class I HLA presents antigen to CD8þ cytolytic T cells, whereas class II HLA mediates the CD4þ T-cell response to infection. Several class I HLA alleles have been found to be associated with viral clearance including HLA-BÃ57 and HLA-CwÃ0102. Conversely, others are associated with persistence, such as HLA-AÃ2301 and HLA-CwÃ04 [24] [25] [26] . Class II HLA genes DQB1Ã0301 and DRB1Ã11 have been associated with viral clearance, and the studies that support these observations have been repeated using several independent cohorts [25, 26] . However, although an association to spontaneous clearance has been observed, the effect is modest and DQB1Ã0301 or DRB1Ã1101 expression in the host has not been associated with treatment-induced HCV elimination.
A significant study by Khakoo et al. [27] showed that individuals homozygous for inhibitory natural killer (NK) cell receptor (KIR2DL3) and the ligand HLA-C1 genes are more likely to clear HCV spontaneously compared with those with other NK receptor-ligand combinations. Improved NK cell activity is postulated to play an important role in reducing HCV replication. However, spontaneous HCV clearance associated with NK cells was observed only in individuals infected via intravenous drug use and not those infected by blood transfusion. It is currently unknown whether it is the amount of virus inocula, route of infection, or other factors that are responsible for this difference. Several studies have examined cytokine genes or expression as immune mediators of spontaneous HCV resolution [3,5, 28, 29] . The most studied of these are IFN-g, TNF-a, IL-10, IL-12, and TGF-b [30] [31] [32] [33] [34] [35] . IFN-g and IL-10 show low-level associations with HCV spontaneous clearance and to some extent SVR to treatment [3, 32, 35, 36] . There is also increasing interest in understanding the role played at the molecular level of genes and regulatory elements downstream of important cytokines, such as interferon-stimulated genes (ISGs). Increased expression in hepatocytes of ISGs prior to treatment has been correlated with poorer response rate [37] . However, ISG as a predictive genetic association factor for HCV clearance has not been fully evaluated. A recent large-scale genetic analysis approach screened 1426 single-nucleotide polymorphisms (SNPs) in 112 candidate genes for spontaneous clearance of HCV. They documented four immune response genes, TNFSF18 (tumor necrosis factor superfamily, member 18), TANK (TRAF family member-associated NF-kB activator), HAVCR1 (hepatitis A virus cellular receptor 1), and IL18BP (IL-18 binding protein), that appeared to play a role in HCV spontaneous clearance [38] . Many of the candidate gene studies described above give leads as to the host immune response genes that might be involved in predicting spontaneous clearance or treatment outcomes. However, other than the HLA polymorphism results, most studies are based on small samples and will require further validation involving the use of larger cohorts of HCV-infected individuals.
Genome-wide association studies that link IL-28B to hepatitis C virus clearance
The genetic tools and the knowledge derived from the Human Genome Project, as well as availability of powerful and relatively inexpensive whole human genome analysis systems from companies such as Illumina (San Diego, California, USA) and Affymetrix (Santa Clara, California, USA), have allowed researchers to embark on studies that were not possible a decade ago. In a powerful genetic approach called genome-wide association study (GWAS), one can examine common genetic variations across large spans of the human genome by analyzing hundreds of thousands of SNPs spanning all chromosomes. The SNPs may be directly involved with or physically linked to genes responsible for a distinct phenotype or trait. Performing GWAS involves four major steps. First step is the selection of the interest group with a well characterized phenotype (e.g., HCV clearance) and a corresponding control group. Second step involves DNA isolation, GWAS genotyping, and data analysis. Third, the data are used in complex statistical analysis to determine whether there are associations of SNPs with the selected trait versus the control group. Fourth, the data are applied to design studies of other independent groups of clinical samples to ascertain whether or not the association is corroborated, as well as studies to elucidate whether the genetic determinant identified by the SNP analysis is responsible for functional characteristics of the trait that is biologically plausible.
In 2009, work from three independent groups reported SNPs in the IL-28B (interferon lambda 3) promoter region associated with treatment response to HCV (Table 1) . All three studies reported SVR of HCV genotype 1-infected participants to treatment with pegylated interferon-a in combination with ribavirin. Ge et al. [39 ] reported a genetic polymorphism in the IL-28B gene on chromosome 19, the SNP rs12979860, associated with HCV treatment-induced clearance. The CC genotype at the SNP was associated with higher response rates to treatment compared with CT or TT genotypes. This association to treatment response held true for all races within the group, including Europeans, African-Americans, and Hispanics. However, there was a clear difference in prevalence of the CC genotype in people of European ancestry versus African-Americans which was postulated to account for approximately half the difference seen from previous studies that described lower response rates to treatment in African-Americans. In the GWAS by Suppiah et al. [40 ] , a well-characterized homogeneous cohort of Australians was analyzed in their initial study and results were confirmed using a second heterogeneous cohort of Australians. The advantage with the primary Australian cohort is that it is a homogeneous population in which differences in age, BMI, and viral load were the same between treatment responders and nonresponders (control group). This study design excluded these factors from having played a role in determining the outcome. They found a SNP rs8099917 in the intergenic region between IL-28A and IL-28B was associated with positive response to treatment-induced recovery. The minor G allele at SNP rs8099917 as opposed to the major T allele was strongly associated with poor virological response to treatment. In a third GWAS paper, Tanaka et al. [41 ] reported results of a study in a Japanese cohort and found that the same SNP as in the study by Suppiah et al. [40 ] (rs8099917) was associated with response to treatment. Once again, the minor G allele was shown to be associated with poor response. In addition, they describe another minor allele at SNP rs12980275 corresponding with poor response. The studies of Suppiah et al. [40 ] and Tanaka et al.
[41 ] documented reduced expression by real-time PCR of IL-28B mRNA in the blood of individuals who were either predicted to or did fail to respond to antiviral treatment. In particular, the homozygous and heterozygous carriers of the minor G allele had significantly reduced IL-28B mRNA expression compared with the homozygous carriers of the major T allele. Thus, three independent studies that sampled different population groups have unequivocally shown that the IL-28B genotype and expression is linked to treatment-induced clearance of HCV, albeit with identified SNP residues that are different (probably reflecting genetic linkage to the etiological polymorphism).
Following the identification of the association of the IL-28B SNP rs12979860 with treatment-induced HCV clearance, Thomas et al. [42 ] examined the association of SNP rs12979860 with spontaneous HCV clearance (Table 1) . They genotyped individuals who spontaneously cleared infection for the SNP rs12979860, compared with a control group of persistently infected individuals (this study included a large number of blood donors with resolved and persistent HCV infections). Interestingly, the same IL-28B SNP rs12979860 shown to be associated with treatment-induced viral clearance was also associated with spontaneous clearance of HCV. Individuals with CC as opposed to CT or TT genotypes had a three-fold higher chance of clearing the virus spontaneously irrespective of race (Fig. 2) . The investigators also examined the global pattern of the rs12979860 C allele frequency in order to gain insight into the geographic frequency distribution.
Interestingly, the comparison of the C allele frequency across six different regions of the world showed that the C allele is a minor allele with reduced frequency in Africa compared with most other regions. This might explain why east Asians and Europeans with higher C allele frequency have higher rates of treatment-induced and spontaneous HCV clearance compared with individuals with African ancestry.
Rauch et al. [43 ] performed a GWAS for individuals with different HCV disease outcomes that included those who spontaneously cleared the virus, responded to treatment (pegylated interferon-a and ribavirin), or were chronically infected (Table 1 ). This study helped answer some of the IL-28B gene polymorphism-related questions raised by the four papers described above. In this study, the population analyzed was exclusively Swiss whites infected with HCV. The SNP rs8099917 (in the IL-28B promoter region) gave the strongest association with spontaneous HCV clearance and no other SNP outside the IL-28B/A locus reached genome-wide significance. The rs8099917 SNP is a T/G allele with the minor G allele identified as the risk allele. The genotypes TT, GT, and GG were analyzed and the results showed that the risk allele frequencies increased from spontaneous clearance followed by treatment-induced clearance to chronic infection indicating treatment failure (Fig. 3 ).
All five papers described here demonstrate the IL-28B gene polymorphism to be one of the strongest genetic effects to be associated with spontaneous and treatmentinduced HCV recovery. However, the underlying mechanism that IL-28B uses to clear HCV and its functional effect needs further work. Interferon-l is a newly discovered family of interferons that includes IL-29 (lambda type 1), IL-28A (lambda type 2), and IL-28B (lambda type 3) [44, 45] . These interferons use the JAK-Stat signal cascade in a similar fashion to interferon-a and induce ISGs [46] . ISGs have been shown to play an important role in HCV treatment outcomes and spontaneous clearance [37] . Interferon lambda 1 (IL-29) has a lower antiviral activity than interferon-a in vitro but was shown to function in conjunction with interferon-a for inhibition of HCV [47, 48] . IL-29 is currently in phase II clinical trials as a treatment for HCV. However, the function of IL-28B and its antiviral effect on HCV is less well understood but will undoubtedly be the focus of extensive further work to understand its role in immunopathogenesis and potential therapeutics.
Importance of hepatitis C virus-infected sample collection by blood centers for large-scale genetic studies
Study by Thomas et al. [42 ] describing the association of the IL-28B SNP with spontaneous HCV clearance used Among the hepatitis C virus (HCV) infected patients, those with treatment failure have higher rates of carriage of the G-risk allele than patients with treatment-induced clearance and patients with spontaneous clearance. , TT; , GT; , GG. Reproduced with permission from [43 ] . Individuals with CC as opposed to CT or TT genotypes have a higher chance of clearing the virus spontaneously irrespective of race. Reproduced with permission from [42 ] .
samples from various HCV patient cohorts as well as HCV-positive samples collected from blood centers for large-scale genetic analysis. Individuals with a history of HCV infection identified by donor screening represent an immense and potentially unique subject pool from which to obtain the sample sizes necessary to identify and subsequently confirm or reject the genetic correlates while minimizing selection bias. Universal implementation of serological screening of blood donors for HCV antibody in 1990 and nucleic acid amplification testing (NAT) for HCV RNA in 1999 has led to the identification of large numbers of antibody confirmed donors with presumptive resolved (RNA-neg/anti-HCV-pos) and chronic (RNA-pos/anti-HCV-pos) infections (Fig. 4 ) [49, 50] . Blood centers in the USA collect approximately 2.6 million units of whole blood and apheresis components from unique first-time donors every year. Given the current seroprevalence of HCV among first-time donors, there are approximately 5000 newly diagnosed HCV infections made in the US blood donor setting annually [50, 51] . The blood donation system, therefore, represents the largest systematic screening program in the USA. Since implementation of NAT screening, US donor screening programs have detected more than 50 donors per year in the viremic preseroconversion phase of HCV infection who can be followed to observe and study the outcome of infection (clearance versus persistence) [52, 53] . NAT has also facilitated routine discrimination of recombinant immunoblot assay (RIBA)-confirmed seropositive donors into those with probable resolved or persistent viremia. At the time of identification and deferral, these persons are notified of their HCV status, including confirmatory test results.
The HCV-infected donor samples (with data to subclassify the infections as viremic preseroconversion window phase, chronic carrier, and resolved infections) obtained from blood centers can include information as to the donor age, sex, and self-identified ethnicity. The blood centers also screen for HIV-1 and HBV by NAT and antibody assays that allows the HCV genetic studies to either include or exclude these samples from co-infected individuals if desired. On a global level, blood banks collaborate extensively, and most of the world's blood supply is now routinely screened for HCV antibodies and RNA, such that sourcing of infected donor samples could be expanded dramatically now that this approach has been demonstrated to be useful in the USA. The advantages and limitations of blood center-derived samples for inclusion in future HCV genetic association studies are given below.
Advantages:
(1) Systematic screening of a cross-section of the society for HCV prevalence.
(2) Large pool of first-time (FT) donors infected with HCV. (3) Donor samples give relevant information on age, sex, ethnicity, and infectious disease screening results. (4) HCV routine testing using NAT, enzyme immunoassay, and RIBA help identify HCV disease outcomes such as acute, spontaneously cleared and chronically infected individuals. (5) Routine blood donor screening also tests for HIV allowing the removal of these samples from genetic studies if necessary. (6) HCV treatment-induced clearance or treatment failure can be studied with a new institutional review board (IRB) approval in a separate study that is designed as a follow-up study of first-time donors screened by blood centers.
Limitations:
(1) Only a snapshot of HCV infection.
(2) Future recalls will require IRB approval.
(3) HCV treatment-induced clearance or treatment failure cannot be studied without new IRB approval and a renewed source of funding.
Conclusion
In this review, we summarized groundbreaking genetic association studies conducted in the last year that have revealed host genes associated with HCV treatmentinduced and spontaneous clearance. These studies are indispensable to understanding the immune correlates of HCV disease pathogenesis and developing new treatment options for HCV-infected persons. The power of large-scale genetic association studies related to HCV can be improved significantly by increasing the number of samples analyzed. Blood collection centers can play a valuable role in this regard. The blood centers are a rich source of uniquely pedigreed-infected donor samples that could substantially increase the number of samples represented in genetic studies examining spontaneous clearance versus chronic HCV infection. Transfusion medicine scientists should strive to actively participate in these important studies, which will likely lead to novel diagnostic, prognostic and therapeutic strategies for HCV.
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